Full-Time
Associate Director
Process Analytics
Confirmed live in the last 24 hours
Vaxcyte
201-500 employees
Develops vaccines for bacterial infections
Compensation Overview
$190k - $197kAnnually
Senior
San Carlos, CA, USA
This position is hybrid.
- PhD in Chemistry/Biochemistry or similar, with 7+ years of industry experience; MS with 10+ years of industry experience; or BS with 15+ years of industry experience.
- Extensive experience in analytical method development, validation, and implementation for biopharmaceutical processes.
- Strong knowledge of analytical techniques such as HPLC and colorimetric assays.
- Experience working with bioconjugates or with regulatory submissions is a plus.
- Proven track record of leading and managing analytical projects in a biopharmaceutical or biotechnology setting.
- Excellent judgment when assessing risk – strong understanding of when to expend resources to reduce risk and when the level of risk is acceptable to move forward.
- Excellent problem-solving skills and ability to work in a fast-paced, dynamic environment.
- Strong communication and interpersonal skills, with the ability to collaborate effectively with cross-functional teams.
- Strong sense of organization, preferably with experience managing timelines using a tool such as Microsoft Project.
- Strong ability to motivate, mentor, and connect with junior team members.
- Curiosity and drive to quickly come up to speed; creativity to solve challenging problems.
- Serve as analytical SME for Conjugation department, representing the department in various cross-functional teams and meetings.
- Review QC method validation protocols and reports to ensure that test method performance meets the needs of the process – if not, collaborate with QC team to bring performance up to process requirements.
- Analyze manufacturing and stability data to identify trends in the process or analytical method performance.
- Contribute to specification setting strategy using analysis of prior data and method performance.
- Contribute to authoring and review of CMC sections in regulatory filings.
- Contribute to analytical method development and optimization for new pipeline programs.
- Coordinate characterization and in-process testing performed within the group.
- Ensure analytical methods used for process development are fit for purpose.
Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA for adult use. Vaxcyte employs advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while eliciting a strong immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial infections on global health.
Company Stage
IPO
Total Funding
$273.3M
Headquarters
Foster City, California
Founded
2013
6 month growth
↑ 23%1 year growth
↑ 61%2 year growth
↑ 132%
Simplify's Take
What believers are saying
- Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
- The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
- The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.
What critics are saying
- The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
- The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.
What makes Vaxcyte unique
- Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
- Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
- The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.
Help us improve and share your feedback! Did you find this helpful?